Gene · 8030
Papers1,913
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,913
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC. | Biochim Biophys Acta Mol Basis Dis | 2024 | 38768929 | PubTator, text mining | PubMed |
| Simpson-Golabi-Behmel syndrome. | Am J Med Genet C Semin Med Genet | 2024 | 38766979 | PubTator, text mining | PubMed |
| Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition. | Anticancer Drugs | 2024 | 38696710 | PubTator, text mining | PubMed |
| RET Fusion Testing in Patients With NSCLC: The RETING Study. | JTO Clin Res Rep | 2024 | 38525319 | PubTator, text mining | PubMed |
| [Stratified application of gene expression in diagnosis of thyroid nodules]. | Zhonghua Bing Li Xue Za Zhi | 2024 | 38433054 | PubTator, text mining | PubMed |
| Adiabatic ionization energies of RuC, RhC, OsC, IrC, and PtC. | J Chem Phys | 2024 | 38391018 | PubTator, text mining | PubMed |
| Long Non-coding RNA 02298 Promotes the Malignancy of HCC by Targeting the miR-28-5p/CCDC6 Pathway. | Biochem Genet | 2024 | 38381357 | PubTator, text mining | PubMed |
| Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer. | NPJ Precis Oncol | 2024 | 38378752 | PubTator, text mining | PubMed |
| Adaptive Clustering for Point Cloud. | Sensors (Basel) | 2024 | 38339567 | PubTator, text mining | PubMed |
| Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer. | Heliyon | 2024 | 38304763 | PubTator, text mining | PubMed |
| Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules. | Medicine (Baltimore) | 2024 | 38277563 | PubTator, text mining | PubMed |
| Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting. | JCO Precis Oncol | 2024 | 38271655 | PubTator, text mining | PubMed |
| Recent Advances in Pyrimidine-Based Drugs. | Pharmaceuticals (Basel) | 2024 | 38256937 | PubTator, text mining | PubMed |
| Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches. | Infect Dis Ther | 2024 | 38240994 | PubTator, text mining | PubMed |
| The mechanism of adipose mesenchymal stem cells to stabilize the immune microenvironment of pelvic floor injury by regulating pyroptosis and promoting tissue repair. | Mater Today Bio | 2024 | 38204481 | PubTator, text mining | PubMed |
| MET fusions are targetable genomic variants in the treatment of advanced malignancies. | Cell Commun Signal | 2024 | 38195556 | PubTator, text mining | PubMed |
| TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort. | Adv Ther | 2024 | 38170436 | PubTator, text mining | PubMed |
| FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect. | Heliyon | 2024 | 38163206 | PubTator, text mining | PubMed |
| Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer. | Cancer Med | 2024 | 38140788 | PubTator, text mining | PubMed |
| The prognostic power of gene mutations in thyroid cancer. | Endocr Connect | 2024 | 38078934 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8030/papers?page=7